Patient eligibility
A total of 83 children and adolescents with a malignant disease
underwent allogeneic hematopoietic cell transplantation (allo-HCT) after
MAC with TBI at Sapporo Hokuyu Hospital between October 1994 and July
2018. All of the patients were enrolled in this study, and their
clinical data were retrospectively evaluated by December
31st, 2019. All enrolled patients were < 20
years old, and their diagnoses of hematologic malignancies were: acute
lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid
leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndromes,
and non-Hodgkin lymphoma. Additionally, the diagnoses for solid tumors
included neuroblastoma and hepatoblastoma. Ninety-two percent of the
diagnoses were hematologic malignant disease. The enrolled patients
received HCT from related or unrelated donors at either complete
remission or incomplete remission.
This study was conducted according to the Declaration of Helsinki and
was approved by the Ethics Committee at Sapporo Hokuyu Hospital,
Sapporo, Japan.